The trajectory of companies tied to the drug's legacy presents a complex investment landscape. While the initial surge generated substantial gains, generic copies have significantly impacted sales . Investing in related pharmaceutical companies now requires a thorough assessment of intellectual property safeguards, evolving patient shifts , and the